Roflumilast Foam 0.3% Secures Major FDA Approval to Treat Seborrheic Dermatitis

Press/Media

Period	18 Dec 2023

Media coverage

Title	Roflumilast Foam 0.3% Secures Major FDA Approval to Treat Seborrheic Dermatitis
Media name/outlet	Drugtopics.com
Country/Territory	United States
Date	18/12/23
URL	https://www.drugtopics.com/view/roflumilast-foam-0-3-secures-major-fda-approval-to-treat-seborrheic-dermatitis
Persons	Peter Lio